Business
Ascletis to Present Study Results of ASC30 Oral Tablet, ASC30 Injection, and Combination of ASC31 and ASC47 at ObesityWeek® 2025
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces multiple poster presentations of its obesity assets including ASC30, and combination of ASC31 and ASC47 at ObesityWeek® 2025 in Atlanta, Georgia.
About this update from Ascletis Pharma, Inc.
[{"type":"text","content":"-Multiple posters being presented on Ascletis' small molecule and peptide obesity programs","length":94,"tagName":"p"},{"type":"text","content":"-Full analysis of 28-day multiple ascending dose study of oral GLP-1R small molecule agonist ASC30 as a late-breaking poster as well as ASC30 once-monthly treatment formulation and once-quarterly maintenance formulation","length":219,"tagName":"p"},{"type":"text","content":"HONG KONG, Oct. 27, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces multiple poster presentations of its obesity assets including ASC30, and combination of ASC31 and ASC47 at ObesityWeek® 2025 in Atlanta, Georgia.","length":257,"tagName":"p"},{"type":"text","content":"Presentation Details: ","length":21,"tagName":"p"},{"type":"text","content":"Abstract Title: A full analysis of 28-Day MAD Study of Oral GLP-1R Biased Small Molecule Agonist ASC30 for obesity","length":119,"tagName":"p"},{"type":"text","content":"Presentation Time: November 4, 2025, 7:30 p.m.-8:30 p.m., EST","length":66,"tagName":"p"},{"type":"text","content":"Abstract Title: ASC30, a Once-Monthly SQ Injected Small Molecule GLP-1RA in Participants with Obesity: A Ph Ib Study","length":121,"tagName":"p"},{"type":"text","content":"Presentation Time: November 4, 2025, 7:30 p.m.-8:30 p.m., EST","length":66,"tagName":"p"},{"type":"text","content":"Abstract Title: GLP-1R/GIPR Peptide Agonist ASC31 + ASC47 Shows 119.6% More Weight Loss than Tirzepatide in DIO Mice","length":116,"tagName":"p"},{"type":"text","content":"Presentation Time: November 4, 2025, 7:30 p.m.-8:30 p.m., EST","length":66,"tagName":"p"},{"type":"text","content":""We're excited to present the continued progress of our robust obesity portfolio, including both small molecules and peptides at ObesityWeek®," said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. "These advancements reflect our strong determination to develop highly differentiated options to treat obesity."","length":347,"tagName":"p"},{"type":"text","content":"About ASC30","length":11,"tagName":"p"},{"type":"text","content":"ASC30 is an investigational GLP-1 receptor (GLP-1R) biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous...